Home » Newsletters » BioWorld Asia

BioWorld Asia

Jan. 11, 2006

View Archived Issues

Symphogen Gets $25M, As Antibody Products Progress

Symphogen A/S raised $25 million in a Series D funding that attracted one new investor. (BioWorld International) Read More

GW Pharma Bringing Cannabis Drug To U.S. For Phase III Work

Seoul University Confirms Stem Cell Work As Fraud

Finnish Institute Gets EUR3M For GMP-Grade Stem Cells

Avidex Gets £5M From Syngenta; Firms Agree To Work On Allergy

Industry Sees Risks In New European Regulatory Tools

LibraGen Initiates Agreement With Pierre Fabre Médicament

Other News To Note

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...